JP2008526893A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526893A5
JP2008526893A5 JP2007550575A JP2007550575A JP2008526893A5 JP 2008526893 A5 JP2008526893 A5 JP 2008526893A5 JP 2007550575 A JP2007550575 A JP 2007550575A JP 2007550575 A JP2007550575 A JP 2007550575A JP 2008526893 A5 JP2008526893 A5 JP 2008526893A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhalable
inhalable pharmaceutical
patient
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007550575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526893A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/000910 external-priority patent/WO2006086107A2/en
Publication of JP2008526893A publication Critical patent/JP2008526893A/ja
Publication of JP2008526893A5 publication Critical patent/JP2008526893A5/ja
Withdrawn legal-status Critical Current

Links

JP2007550575A 2005-01-10 2006-01-10 肺における吸入可能なインスリンの自然増加を最少化するための方法及び組成物 Withdrawn JP2008526893A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64305405P 2005-01-10 2005-01-10
PCT/US2006/000910 WO2006086107A2 (en) 2005-01-10 2006-01-10 Methods and compositions for minimizing accrual of inhalable insulin in the lungs

Publications (2)

Publication Number Publication Date
JP2008526893A JP2008526893A (ja) 2008-07-24
JP2008526893A5 true JP2008526893A5 (cg-RX-API-DMAC10.html) 2009-03-05

Family

ID=36793549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007550575A Withdrawn JP2008526893A (ja) 2005-01-10 2006-01-10 肺における吸入可能なインスリンの自然増加を最少化するための方法及び組成物

Country Status (7)

Country Link
US (1) US20060153778A1 (cg-RX-API-DMAC10.html)
EP (1) EP1858486A2 (cg-RX-API-DMAC10.html)
JP (1) JP2008526893A (cg-RX-API-DMAC10.html)
AU (1) AU2006213084A1 (cg-RX-API-DMAC10.html)
CA (1) CA2592776A1 (cg-RX-API-DMAC10.html)
MX (1) MX2007008379A (cg-RX-API-DMAC10.html)
WO (1) WO2006086107A2 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
US20070027063A1 (en) * 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
AU2014271222B2 (en) * 2005-09-14 2016-04-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Glp-1에 의한 유해 효과의 예방 방법
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) * 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US20190262557A1 (en) * 2010-03-04 2019-08-29 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
US11110151B2 (en) * 2008-08-11 2021-09-07 Mannkind Corporation Composition and method for reducing hypoglycemia events in diabetes treatment
TWI494123B (zh) * 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
SI2379100T1 (sl) * 2009-01-08 2015-02-27 Mannkind Corporation Zdravljenje hiperglikemije z GLP-1
AU2014200960B2 (en) * 2009-03-04 2016-02-11 Mannkind Corporation An improved dry powder drug delivery system
MX2011009251A (es) * 2009-03-04 2011-11-18 Mannkind Corp Sistema mejorado de suministro de farmaco en polvo seco.
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
SG10201403147SA (en) * 2009-06-12 2014-10-30 Mannkind Corp Diketopiperazine microparticles with defined isomer contents
AU2010259943C1 (en) * 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2000301A (en) * 1932-04-02 1935-05-07 Norman Confections Inc Progressive container
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
ES2395096T3 (es) * 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics

Similar Documents

Publication Publication Date Title
Nishimura High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects
Shankar et al. Isoflurane therapy for severe refractory status asthmaticus in children
Diaz et al. Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis
JP2015110631A5 (cg-RX-API-DMAC10.html)
JP2011500850A5 (cg-RX-API-DMAC10.html)
Defresne et al. Recruitment of lung volume during surgery neither affects the postoperative spirometry nor the risk of hypoxaemia after laparoscopic gastric bypass in morbidly obese patients: a randomized controlled study
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
Morán et al. Heat and moisture exchangers and heated humidifiers in acute lung injury/acute respiratory distress syndrome patients. Effects on respiratory mechanics and gas exchange
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
MXPA03011861A (es) Particulas para inhalacion que tienen rapidas propiedades de liberacion.
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
JP2023523557A5 (cg-RX-API-DMAC10.html)
Eden et al. Prolonged smoldering Douglas fir smoke inhalation augments respiratory resistances, stiffens the aorta, and curbs ejection fraction in hypercholesterolemic mice
JP2007520507A5 (cg-RX-API-DMAC10.html)
Brain Unlocking the opportunity of tight glycaemic control: Inhaled insulin: safety
CN102133319B (zh) 一种平喘止咳的药物及其制备方法
WO2005041922A3 (en) Composition
Berkowitz et al. Laryngeal foreign bodies in children revisited
DE60308497D1 (de) Pulverzubereitungen zur inhalation
Araújo et al. Transitory increased blood pressure after upper airway surgery for snoring and sleep apnea correlates with the apnea-hypopnea respiratory disturbance index
Chattopadhyay et al. Respiratory response to tobacco dust exposure among biddi binders: A follow up and bronchodilator study
JP2017524732A5 (cg-RX-API-DMAC10.html)
Hall Wearing a noseclip improves nebulised aerosol delivery
Ahsan et al. A case report on aspiration pneumonia of a Jamunapari buck